Novavax Inc
NVAX8.250USD
+0.380+4.83%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
1.34BMarket Cap
3.94P/E TTM
More Details of Novavax Inc Company
Novavax, Inc. is a biotechnology company. It is focused on addressing global health challenges through its vaccines and its proven technology platform, including protein-based nanoparticles and its Matrix-M adjuvant. Matrix-M can be used to create vaccines for a variety of diseases to help tackle some of the pressing health challenges. Its proprietary Matrix-M adjuvant, when added to vaccines, has been shown to help induce a stronger and longer-lasting immune response. Its recombinant protein-based nanoparticle technology has been shown to be highly immunogenetic. Its technology platform is used in its authorized COVID-19 vaccine and the R21/Matrix-M adjuvant malaria vaccine. Its late-stage programs include a COVID-19-Influenzavaccine candidate, and an influenza vaccine candidate. R21/Matrix-M adjuvant malaria vaccine, a malaria vaccine developed by its partner. It provides Matrix-M adjuvant for use in various programs in preclinical and clinical stage, and preclinical investigations.
Novavax Inc Info
Ticker SymbolNVAX
Company nameNovavax Inc
IPO dateMay 16, 1973
CEOJacobs (John C)
Number of employees952
Security typeOrdinary Share
Fiscal year-endMay 16
Address21 Firstfield Rd
CityGAITHERSBURG
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code20878
Phone12402682000
Websitehttps://www.novavax.com/?locale=US
Ticker SymbolNVAX
IPO dateMay 16, 1973
CEOJacobs (John C)
Company Executives of Novavax Inc
Name
Name/Position
Position
Shareholding
Change
Mr. John C. Jacobs
Mr. John C. Jacobs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
180.80K
+44065.00%
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Director
Independent Director
71.31K
+10420.00%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Director
Independent Director
64.76K
+10420.00%
Mr. Mark J. Casey
Mr. Mark J. Casey
Executive Vice President, Chief Legal Officer, Company Secretary
Executive Vice President, Chief Legal Officer, Company Secretary
61.16K
+29186.00%
Ms. Elaine O'hara
Ms. Elaine O'hara
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
57.48K
--
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
38.91K
+3800.00%
Ms. Rachel K. King
Ms. Rachel K. King
Independent Director
Independent Director
35.61K
+10420.00%
Dr. Ruxandra Draghia-Akli, M.D., Ph.D.
Dr. Ruxandra Draghia-Akli, M.D., Ph.D.
Executive Vice President, Head of Research & Development
Executive Vice President, Head of Research & Development
8.21K
+8209.00%
Mr. Gregg Huber Alton, J.D.
Mr. Gregg Huber Alton, J.D.
Independent Director
Independent Director
--
--
Ms. Margaret G. (Margie) Mcglynn
Ms. Margaret G. (Margie) Mcglynn
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. John C. Jacobs
Mr. John C. Jacobs
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
180.80K
+44065.00%
Mr. David M. (Dave) Mott
Mr. David M. (Dave) Mott
Independent Director
Independent Director
71.31K
+10420.00%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Director
Independent Director
64.76K
+10420.00%
Mr. Mark J. Casey
Mr. Mark J. Casey
Executive Vice President, Chief Legal Officer, Company Secretary
Executive Vice President, Chief Legal Officer, Company Secretary
61.16K
+29186.00%
Ms. Elaine O'hara
Ms. Elaine O'hara
Executive Vice President, Chief Strategy Officer
Executive Vice President, Chief Strategy Officer
57.48K
--
Mr. Richard J. (Rick) Rodgers
Mr. Richard J. (Rick) Rodgers
Independent Director
Independent Director
38.91K
+3800.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
56.78M
80.60%
Rest of the world
13.01M
18.47%
Europe
655.00K
0.93%
Canada
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.50%
Shah Capital Management, Inc.
8.96%
BlackRock Institutional Trust Company, N.A.
6.90%
State Street Investment Management (US)
4.43%
Sanofi SA
4.23%
Other
65.98%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.50%
Shah Capital Management, Inc.
8.96%
BlackRock Institutional Trust Company, N.A.
6.90%
State Street Investment Management (US)
4.43%
Sanofi SA
4.23%
Other
65.98%
Shareholder Types
Shareholders
Proportion
Investment Advisor
26.84%
Investment Advisor/Hedge Fund
21.72%
Hedge Fund
9.50%
Corporation
8.23%
Research Firm
4.30%
Pension Fund
0.65%
Individual Investor
0.56%
Bank and Trust
0.45%
Venture Capital
0.08%
Other
27.66%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
546
103.21M
63.51%
-5.15M
2025Q3
546
95.10M
58.55%
-6.89M
2025Q2
553
108.80M
66.99%
-11.74M
2025Q1
575
113.82M
70.29%
-16.33M
2024Q4
593
111.51M
69.72%
-5.93M
2024Q3
597
103.31M
64.96%
-4.25M
2024Q2
652
92.80M
65.79%
-10.97M
2024Q1
753
86.51M
64.06%
-11.91M
2023Q4
848
86.68M
74.23%
+6.21M
2023Q3
919
70.31M
60.51%
-6.00M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
15.16M
9.33%
-238.65K
-1.55%
Sep 30, 2025
Shah Capital Management, Inc.
13.39M
8.24%
+1.65M
+14.05%
Nov 10, 2025
BlackRock Institutional Trust Company, N.A.
11.21M
6.9%
+40.06K
+0.36%
Sep 30, 2025
State Street Investment Management (US)
7.20M
4.43%
+372.47K
+5.46%
Sep 30, 2025
Sanofi SA
6.88M
4.23%
--
--
Sep 30, 2025
SK Bioscience Co., Ltd.
6.50M
4%
--
--
May 10, 2024
UBS Financial Services, Inc.
3.33M
2.05%
+1.16M
+53.67%
Sep 30, 2025
D. E. Shaw & Co., L.P.
4.27M
2.63%
+333.12K
+8.45%
Sep 30, 2025
Coatue Management, L.L.C.
3.84M
2.36%
--
--
Sep 30, 2025
Geode Capital Management, L.L.C.
3.79M
2.33%
+23.71K
+0.63%
Sep 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
ProShares Nanotechnology ETF
2.78%
iShares Genomics Immunology and Healthcare ETF
2.63%
Virtus LifeSci Biotech Products ETF
1.88%
ALPS Medical Breakthroughs ETF
0.55%
State Street SPDR S&P Biotech ETF
0.53%
First Trust Small Cap Value AlphaDEX Fund
0.51%
Direxion Daily S&P Biotech Bull 3X Shares
0.33%
First Trust Small Cap Core Alphadex Fund
0.19%
ProShares Ultra Nasdaq Biotechnology
0.13%
Invesco Nasdaq Biotechnology ETF
0.13%
View more
ProShares Nanotechnology ETF
Proportion2.78%
iShares Genomics Immunology and Healthcare ETF
Proportion2.63%
Virtus LifeSci Biotech Products ETF
Proportion1.88%
ALPS Medical Breakthroughs ETF
Proportion0.55%
State Street SPDR S&P Biotech ETF
Proportion0.53%
First Trust Small Cap Value AlphaDEX Fund
Proportion0.51%
Direxion Daily S&P Biotech Bull 3X Shares
Proportion0.33%
First Trust Small Cap Core Alphadex Fund
Proportion0.19%
ProShares Ultra Nasdaq Biotechnology
Proportion0.13%
Invesco Nasdaq Biotechnology ETF
Proportion0.13%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
